BCAL Diagnostics

BCAL Diagnostics Equity

The The Equity of BCAL Diagnostics (BDX.AX) as of Oct 18, 2026 is 6.22 M AUD. In the previous year, The Equity was 8.59 M AUD — a change of -27.57% (lower).

Equity

6.22 MAUD

YoY

-27.57%

Last updated:

In 2025, BCAL Diagnostics's equity was 6.22 M AUD, a -27.57% increase from the 8.59 M AUD equity in the previous year.

The BCAL Diagnostics Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
-81,900.00 AUD
Jan 1, 2019
488,200.00 AUD
Jan 1, 2020
438,900.00 AUD
Jan 1, 2021
3.61 M AUD
Jan 1, 2022
9.64 M AUD
Jan 1, 2023
5.21 M AUD
Jan 1, 2024
8.59 M AUD
Jan 1, 2025
6.22 M AUD
The BCAL Diagnostics Equity history
YEAREquityYoY
6.22 MAUD-27.57%
8.59 MAUD+64.72%
5.21 MAUD-45.91%
9.64 MAUD+167.26%
3.61 MAUD+721.80%
438,900.00AUD-10.10%
488,200.00AUD-696.09%
-81,900.00AUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

BCAL Diagnostics Stock analysis

What does BCAL Diagnostics do? BCAL Diagnostics Ltd, based in Sydney, Australia, operates in the Health Care sector within the Biotechnology industry. The company develops innovative blood screening tests for early breast cancer detection, focusing on a lipid biomarker-based approach known as the BCAL test. This technology complements existing imaging methods like mammograms and aims to support screening and monitoring for women of all ages and backgrounds. BCAL Diagnostics has partnered with Precion Inc. to advance clinical trials and regulatory approvals for its diagnostic solutions. BCAL Diagnostics is one of the most popular companies on Eulerpool.

Equity Details

Analyzing BCAL Diagnostics's Equity

BCAL Diagnostics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding BCAL Diagnostics's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating BCAL Diagnostics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

BCAL Diagnostics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in BCAL Diagnostics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about BCAL Diagnostics stock

The Equity of BCAL Diagnostics is 6.22 M AUD in 2025.

The Equity of BCAL Diagnostics changed from 8.59 M AUD to 6.22 M AUD, representing a -27.57% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity BCAL Diagnostics since 2006 – with annual values, charts, and detailed analysis.

The Equity's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's BCAL Diagnostics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — BCAL Diagnostics

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — BCAL Diagnostics